Enveric Biosciences Announces Pricing of $10 Million Public Offering
February 11, 2022
Ryan Allway February 11th, 2022 Psychedelics, Top News NAPLES, Fla., Feb. 11, 2022 /PRNewswire/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the pricing of its previously announced underwritten public offering of 20,000,000 shares of its common... Read more
Improving on Psychedelics for Therapy: Interview with Mindset Pharma
February 11, 2022
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Silo Wellness Inc. Announces: Global Mushroom Brand Marley One Sponsors Metaverse Concert Series ‘For the Love of Hip Hop’
February 10, 2022
Ryan Allway February 10th, 2022 Psychedelics, Top News Virtual concert features Big Boi, Goodie Mob, Ying Yang Twins, Little Scrappy, Young Dro and more Montego Bay, Jamaica–(Newsfile Corp. – February 10, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading... Read more
Irwin Naturals Begins Rollup of Psychedelic Mental Health Clinics
February 9, 2022
Ryan Allway February 9th, 2022 Psychedelics, Top News LOS ANGELES, Feb. 09, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has taken the first step in the execution of its ketamine clinic rollup strategy – a move... Read more
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Clearmind Medicine Secures CAD$1.6 Million in Private Placement
February 8, 2022
Ryan Allway February 8th, 2022 Psychedelics, Top News Clearmind and Medigus, the investor, intend to form a joint venture in the field of food industry, based on Clearmind’s unique psychedelics IP TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the “Company“), a... Read more
Optimi Health Dealer’s License Granted by Health Canada
February 7, 2022
Optimi Health to become a global leader in all-natural psilocybin production VANCOUVER, BC (February 7, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased... Read more
Tryp Therapeutics Announces $2,000,000 Financing and Changes in Management, Board of Directors
February 4, 2022
Ryan Allway February 4th, 2022 Psychedelics, Top News SAN DIEGO – February 4, 2022 – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to announce a non-brokered private placement (the “Placement“)... Read more
Lobe Sciences Ltd. Acquires Securities of Ionic Brands Corp.
February 3, 2022
Ryan Allway February 3rd, 2022 Psychedelics, Top News Vancouver, British Columbia–(Newsfile Corp. – February 3, 2022) – Lobe Sciences Ltd. (the “Acquiror“) announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 3, 2022, it acquired 47,065,647 common shares in the capital of Ionic Brands... Read more
Entheon Biomedical Announces the Approval of DMT Clinical Trial
February 3, 2022
Vancouver, British Columbia–(Newsfile Corp. – February 03, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by... Read more
